Antiparasitic agent-9 (compound 47) is a highly effective and orally administered antiparasitic agent, demonstrating significant efficacy against the human parasite [1].

Antiparasitic agent-9 (compound 47) administered orally at 15 mg/kg twice daily for seven days significantly reduces the adult worm burden by 59% in the jird L. sigmodontis infection model. When given once at varying doses (2 mg/kg intravenously, 10 and 30 mg/kg orally), it shows a brain to plasma ratio of 0.08, indicating minimal brain penetration. In male CD-1 mice, a 30 mg/kg oral dose achieved a maximum concentration (C max) of 13.9 μM, an absorption time (T max) of 0.5 hours, and an area under the curve (AUC) from 0 to infinity of 121 μM·h. The compound demonstrated a clearance (CL) rate of 3.6 mL/min/kg, a steady-state volume of distribution (Vd ss) of 0.74 mL/kg, a bioavailability (F) of 57%, and an efflux ratio (ER) of 12, highlighting its pharmacokinetic properties.